A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 70
Summary
- Conditions
- Dyslipidemias
- Non.Alcoholic Fatty Liver Disease
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This study will conduct to evaluate the efficacy of liver fat lowering and safety of rosuvastatin 5mg alone or in combination with rosuvastatin 5mg / ezetimibe 10mg for 6 months.Masking: None (Open Label)Masking Description: Open labelPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 19 years and 80 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03434613
- Collaborators
- Not Provided
- Investigators
- Not Provided